ESMO 2022 | The potential applications of ctDNA in melanoma

Matteo Carlino, FRACP, PhD, University of Sydney and Westmead Hospital, Sydney, Australia, discusses utilizing ctDNA-based approaches in melanoma, including as a predictive marker of response and to help in the differentiation of pseudoprogression from true progression. ctDNA can additionally be used for the early identification of the development of resistance and assessing risk of recurrence in resected disease. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.